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was a strong correlation between total plaque volume in a vessel and plaque area at the 
site with worst lesion. (Figure) 
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Conclusion: Plaque area of the most severe lesion in a coronary artery reflects totat 
plaque burden in patients with mild, moderate or severe athercsclerosis. This finding 
adds to the evidence that coronary atherosclerosis a diffuse and generalized process. 
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Background: The mechanism of lumen enlargement after angioplasty for in-stent rest- 
enosis (ISR) is a combination of further stent expansion and redistribution of intimal 
hyperplasia. However, contribution of further stent expansion and redistribution of intimal 
hyperplasia to lumen enlargement may be different between focal and diffuse in-stent 
restesnosis. 
Methods: Intravascular ultrasound (IVUS) was performed in 47 lesions with ISR before 
and after balloon angioplasty. Those were divided in two groups according to lesion 
length measured by QCA: 1) focal (<20mm, n=21) and 2) diffuse (>~20mm, n=26). IVUS 
images of the stented segment were measured every 0.5 mm. 
Conclusions: Plaque re-distribution within stent is the main mechanism of lumen 
enlargement during balloon angioplasty in focal ISR, In contrast, furthur stent expansion 
is the main mechanism for diffuse ISR. 
Results 
Focal (n=21) Diffuse (n=26) p Value 
Mean reference lumen CSA (mm 2) 8.0-i-_4.6 6.5:~?..1 0.30 
Pre-intervention 
Minimal lumen CSA (mm 2) 1.9±0.8 1.6_+0.6 0.21 
Stent CSA (ram 2) 7.1±3.1 5.7_+1.6 0.06 
Neointima CSA (mm 2) 5.2+2.7 4.0±1.4 0~08 
Mean lumen CSA (mm 2) 4.0±1.8 3.0±1.2 0.04 
Mean stent CSA (mm 2) 7.3_+3.1 6.3_+1.4 0.17 
Mean neointima CSA (mm 2) 3.3_+1.7 3.2±1.1 0.95 
Post-intervention 
Minimal lumen CSA (mm 2) 5.2±2.0 5.1_+2.0 0.84 
Stent CSA (ram 2) 8.1 _+3.1 7.5±2.7 0.43 
Neointima CSA (mm 2) 2.9~1.9 2.3+1.2 0.27 
Mean lumen CSA (mm 2) 5.6_+1.9 5.9±2.0 0.67 
Mean stent CSA (mm 2) 8.1_+2.8 8.2+~.2 0.98 
Mean neointima CSA(mm 2) 2.5±1.2 2.3+0.8 0.45 
AStent CSNALumen CSA 0.27 0.53 0.03 
ANeointima CSA/ALumen CSA 0.73 0.47 0.03 
/',Mean lumen CSA (mm 2) 1.6±1.1 2.8±1.9 0.007 
AMean stent CSA (mm 2) 0.9~1.1 1.9±1.6 0.01 
AMean neointima CSA (mm 2) -0.7+0.7 -1.0~0.9 0.38 
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Background: We previously reported the long-term efficacy of sirolimus-coated BX 
Velocity stent (Cypher TM) to treat de novo coronary lesions. The objective of this study 
was to assess the safety and efficacy of this new drog-eluting stent for the treatment of 
in-stent restenosis (ISR). Methods: Forty patients with ISR in native coronary arteries 
were successfully treated with >1 Cypher TM stent (1.4 stents/lesion) in this prospective 
registry. Angiography and volumetric IVUS quantification was performed in all pts at 
baseline and will be repeated at 4 months to determine the amount of neo-intimal prolif- 
eration, Reeults: Thusfar. 22 pts have completed anglo and IVUS follow-up. Mean age 
was 56+13 years, 82% were male and 15% were diabetics. Lesion length was 
17.2+9.7mm. At present (mean follow-ups102+64 days) the incidence of major cardiac 
events is 2.5% (1 sudden death at 4 months, no MIs, and no repeat revascularization). 
Angiographic and IVUS data are in the table. 
Post procedure Follow-up 
Angiogrephy 
Referrence diameter (mm) 2.85_+0.32 2.84_+0.41 
Binary restenosis (%) N/A 0 
Minimum lumen diameter (ram) 2.71_+0.26 2.63±0.31 
Late loss (mm) N/A 0.09 
IVUS 
Stent volume (mm3) 140.2±49.7 140.2+49.7 
Lumen volume (mm3) 140.2±49.7 134.5±48.9 
Intimal hyperplasia volume (mm3) N/A 6.3±5.6 
% of obstruction N/A 5% 
Conclusion: In this preliminary registry, the treatment of in-stent restenosis using the 
Cypher TM stent showed 1) no angiographic restenosis; 2) infrequent cardiac events 
(2.5%); and 3) minimal (5%) IVUS in-stent obstruction. Follow-up of the complete patient 
cohort will be presented 
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Background: Sirolimus-eluting stent (SES) is emerging as a potential solution for the 
prevention of restenosis. However, we have to establish that SES does not produce edge 
restenosis as seen in radioactive stents. The objective of this study is to compare the 
edges of Sirolimus-eluting Bx VELOCITY tm stent (Cordis) with those of uncoated Bx 
VELOCITY tm stent (US) in the RAVEL study, a double-blind, randomized and controlled 
trial Methods: We assessed the post-procedural and 6-month follow-up angiograms of 
238 patients enrolled in the RAVEL study. Quantitative coronary angiography (QCA) was 
performed with the CAAS II system. Three segments were selected for QCA : the stented 
segment and two edge segments that were axially 5 mm proximal and distal to the stent 
margins. Results: 212 patients had angiographic follow-up. (105 patients in SES group, 
107 patients in US group). 
MLDpoet(mm) MLD6-month(mm) P-value LeteLou  
oroxlmal edce SES 2.47_+0.53 2.41±0.58 NS 0.05±0.40 
US 2.46_+0.54 2.18_+0.63 .001 0.29~0.48 
In-stent SES 2.43±0.41 2.42+0.49 NS -0.01±0.33 
US 2.41±0.40 1.64+0.58 .000 0.80~).53 
distal edoe SES 2.13+0.47 2.20~0.51 NS -0.10~O.30 
US 2.21±0.51 2.11_+0.50 NS 0.11¢0.43 
In each segment of SES, postprocedural MLD remained basically unchanged at follow- 
up. In addition, the late loss of SES group is significantly lower than that of the US 
group(P=0.0001). Conclusion: Elution of Sirolimus not only fully inhibits neointimal 
hyperplasia within the stent but also prevents the edge effect seen mainly proximally with 
the uncoated stent. 
